Can-Fite Reports Positive Rheumatoid Arthritis Treatment Results

– The 12-week Phase IIb study involving 79 patients with active rheumatoid arthritis met all its primary efficacy endpoints. – Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board:CANFY)  reports More...

Can-Fite Raises NIS 21.3 Million ($5.9 Million) Ahead Of NYSE Listing

– Can-Fite will use the proceeds to increase its shareholders’ equity to meet the criteria for listing its ADRs on the NYSE. –  Can-Fite CEO Pnina Fishman – Can-Fite BioPharma Ltd. (TASE:CFBI; More...